Mechanisms underlying current and future anti-obesity drugs

被引:86
作者
Adan, Roger A. H. [1 ]
机构
[1] Univ Med Ctr Utrecht, Rudolf Magnus Inst, Dept Neurosci & Pharmacol, Utrecht, Netherlands
关键词
satiety; monoamines; weight loss drug; RECEPTOR-EXPRESSING NEURONS; SUSTAINED WEIGHT-LOSS; PLASMA GHRELIN LEVELS; FOOD-INTAKE; COMBINATION THERAPY; CONTROLLED-RELEASE; BODY-COMPOSITION; ENERGY-BALANCE; OBESE; DOPAMINE;
D O I
10.1016/j.tins.2012.12.001
中图分类号
Q189 [神经科学];
学科分类号
071006 [神经生物学];
摘要
Regulation of body weight is organized by distributed brain circuits that use a variety of neuropeptides and transmitters, and that are responsive to endocrine and metabolic signals. Targeting of these circuits with novel pharmaceutical drugs would be helpful additions to lifestyle interventions for the treatment of obesity. The recent FDA approval of two anti-obesity drugs holds promise in a field in which previous drugs were removed from clinical use because of unacceptable psychiatric and cardiovascular side effects. Here, the modes of action of anti-obesity drugs are reviewed.
引用
收藏
页码:133 / 140
页数:8
相关论文
共 101 条
[1]
Peptide YY3-36 inhibits both anorexigenic proopiomelanocortin and orexigenic neuropeptide Y neurons:: Implications for hypothalamic regulation of energy homeostasis [J].
Acuna-Goycolea, C ;
van den Pol, AN .
JOURNAL OF NEUROSCIENCE, 2005, 25 (45) :10510-10519
[2]
Antel J., 2011, APPETITE CONTROL, V209, P433
[4]
Positive Effect of Baclofen on Body Weight Reduction in Obese Subjects: A Pilot Study [J].
Arima, Hiroshi ;
Oiso, Yutaka .
INTERNAL MEDICINE, 2010, 49 (19) :2043-2047
[5]
New targets for obesity pharmacotherapy [J].
Aronne, L. J. ;
Thornton-Jones, Z. D. .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2007, 81 (05) :748-752
[6]
Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide [J].
Astrup, A. ;
Carraro, R. ;
Finer, N. ;
Harper, A. ;
Kunesova, M. ;
Lean, M. E. J. ;
Niskanen, L. ;
Rasmussen, M. F. ;
Rissanen, A. ;
Rossner, S. ;
Savolainen, M. J. ;
Van Gaal, L. .
INTERNATIONAL JOURNAL OF OBESITY, 2012, 36 (06) :843-854
[7]
Effect of tesofensine on bodyweight loss, body composition, and quality of life in obese patients: a randomised, double-blind, placebo-controlled trial [J].
Astrup, Arne ;
Madsbad, Sten ;
Breum, Leif ;
Jensen, Thomas J. ;
Kroustrup, Jens Peter ;
Larsen, Thomas Meinert .
LANCET, 2008, 372 (9653) :1906-1913
[8]
Deconstruction of a neural circuit for hunger [J].
Atasoy, Deniz ;
Betley, J. Nicholas ;
Su, Helen H. ;
Sternson, Scott M. .
NATURE, 2012, 488 (7410) :172-+
[9]
Gut hormone PYY3-36 physiologically inhibits food intake [J].
Batterham, RL ;
Cowley, MA ;
Small, CJ ;
Herzog, H ;
Cohen, MA ;
Dakin, CL ;
Wren, AM ;
Brynes, AE ;
Low, MJ ;
Ghatei, MA ;
Cone, RD ;
Bloom, SR .
NATURE, 2002, 418 (6898) :650-654
[10]
Combination therapy with naltrexone and bupropion for obesity [J].
Billes, Sonja K. ;
Greenway, Frank L. .
EXPERT OPINION ON PHARMACOTHERAPY, 2011, 12 (11) :1813-1826